Recor Medical ex-CEO Lara Barghout joins Medtronic

{
  "signal_id": "15850b06-b12f-ef77-705c-a6c9db1b7727",
  "signal_type": "news",
  "signal_subtype": "hires",
  "detected_at": "2026-09-16T19:52:11+00:00",
  "company": {
    "name": "Medtronic",
    "domain": "medtronic.com"
  },
  "data": {
    "url": "https://www.medtechdive.com/news/recor-medical-ex-ceo-lara-barghout-joins-medtronic/830598/",
    "title": "Recor Medical ex-CEO Lara Barghout joins Medtronic",
    "author": "Susan Kelly",
    "contact": "Lara Barghout",
    "excerpt": "Barghout, who led Recor when it won FDA approval of the first renal denervation treatment for hypertension, is the new president of Medtronic’s Interventional Cardiology Therapies business. Name: Lara Barghout New title: President of Interventional Cardiology Therapies, Medtronic Previous title: CEO, Recor Medical Former Recor Medical CEO Lara Barghout has been named president of Medtronic’s Interventional Cardiology Therapies operating unit. The ICT business includes Medtronic’s structural heart, coronary and hypertension management product lines. “Lara brings proven leadership in the cardiovascular space and a global, future-ready mindset to the recently integrated ICT team,” Medtronic said in an emailed statement. “Under her leadership, we will continue to strengthen our ability to serve the interventional cardiology customer, elevate breakthrough innovation, and accelerate our ability to digitally transform the cath lab.” Barghout was CEO of Recor when its Paradise device became the first renal denervation system approved by the Food and Drug Administration to treat uncontrolled high blood pressure. Recor won the approval just weeks before Medtronic got the agency’s nod for its competing Symplicity Spyral device, following a divided advisory panel vote . Barghout, who joined Recor as president and CEO in January 2023, left the Otsuka Medical Devices subsidiary in February...",
    "summary": "Medtronic has hired former Recor Medical CEO Lara Barghout as the new president of its Interventional Cardiology Therapies business.",
    "planning": false,
    "image_url": "https://imgproxy.divecdn.com/dpZOGK7uZq3mfriZ28y4Uu0aelqkErUEGH0Sj6aiwV4/g:nowe:224:37/c:1763:996/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9IZWFkc2hvdDFfZ1ZkSmJPVy5qcGc=.webp",
    "job_title": "President of Interventional Cardiology Therapies",
    "confidence": 0.95,
    "published_at": "2026-09-16T19:52:11Z",
    "job_title_tags": [
      "directors",
      "management"
    ],
    "article_sentence": "Barghout, who led Recor when it won FDA approval of the first renal denervation treatment for hypertension, is the new president of Medtronic’s Interventional Cardiology Therapies business.",
    "related_company_name": "Recor Medical",
    "related_company_domain": "recormedical.com"
  }
}

curl https://signals.autobound.ai/v1/signals/15850b06-b12f-ef77-705c-a6c9db1b7727 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"medtronic.com","limit":20}'